[go: up one dir, main page]

WO2007065808A3 - Agonistes du récepteur du neuropeptide-2 - Google Patents

Agonistes du récepteur du neuropeptide-2 Download PDF

Info

Publication number
WO2007065808A3
WO2007065808A3 PCT/EP2006/068924 EP2006068924W WO2007065808A3 WO 2007065808 A3 WO2007065808 A3 WO 2007065808A3 EP 2006068924 W EP2006068924 W EP 2006068924W WO 2007065808 A3 WO2007065808 A3 WO 2007065808A3
Authority
WO
WIPO (PCT)
Prior art keywords
neuropeptide
agonists
receptor
obesity
diabetes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2006/068924
Other languages
English (en)
Other versions
WO2007065808A2 (fr
Inventor
Karin Conde-Knape
Waleed Danho
George Ehrlich
Nader Fotouhi
David C Fry
Wajiha Khan
Anish Konkar
Cristina Martha Rondinone
Joseph Swistok
Rebecca Anne Taub
Jefferson W Tilley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37964711&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2007065808(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to KR1020087016291A priority Critical patent/KR101059602B1/ko
Priority to CA002630649A priority patent/CA2630649A1/fr
Priority to ES06830133T priority patent/ES2381497T3/es
Priority to BRPI0619573-3A priority patent/BRPI0619573A2/pt
Priority to AU2006324076A priority patent/AU2006324076A1/en
Priority to EP06830133A priority patent/EP1962959B1/fr
Priority to NZ568772A priority patent/NZ568772A/en
Priority to JP2008543768A priority patent/JP5000663B2/ja
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Priority to AT06830133T priority patent/ATE549350T1/de
Publication of WO2007065808A2 publication Critical patent/WO2007065808A2/fr
Publication of WO2007065808A3 publication Critical patent/WO2007065808A3/fr
Priority to IL191636A priority patent/IL191636A/en
Priority to NO20082445A priority patent/NO20082445L/no
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57545—Neuropeptide Y
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des agonistes du récepteur du neuropeptide-2 de formule (I) ainsi que des sels, des dérivés et des fragments acceptables sur le plan pharmaceutique de ceux-ci. Les substituants de ladite formule ont la signification indiquée dans la description. Ces composés, ainsi que les compositions pharmaceutiques les contenant, sont utiles pour le traitement de maladies comme l'obésité et le diabète.
PCT/EP2006/068924 2005-12-07 2006-11-27 Agonistes du récepteur du neuropeptide-2 Ceased WO2007065808A2 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
AT06830133T ATE549350T1 (de) 2005-12-07 2006-11-27 Neuropeptid-2-rezeptor-agonisten
EP06830133A EP1962959B1 (fr) 2005-12-07 2006-11-27 Agonistes du récepteur du neuropeptide-2
CA002630649A CA2630649A1 (fr) 2005-12-07 2006-11-27 Agonistes du recepteur du neuropeptide-2
ES06830133T ES2381497T3 (es) 2005-12-07 2006-11-27 Agonistas del receptor del neuropéptido-2
BRPI0619573-3A BRPI0619573A2 (pt) 2005-12-07 2006-11-27 agonista receptor de neuropeptìdeo-2, formulações farmacêuticas, uso de agonista receptor de neuropeptìdeo-2 e método de tratamento de uma doença modulada por agonistas receptores de neuropeptìdeos-2
AU2006324076A AU2006324076A1 (en) 2005-12-07 2006-11-27 Neuropeptide-2 receptor-agonists
NZ568772A NZ568772A (en) 2005-12-07 2006-11-27 Truncated analogs of the peptide pYY3-36 that are neuropeptide-2 receptor-agonists
KR1020087016291A KR101059602B1 (ko) 2005-12-07 2006-11-27 신경펩타이드 2 수용체 작용물질
JP2008543768A JP5000663B2 (ja) 2005-12-07 2006-11-27 神経ペプチド２受容体アゴニスト
IL191636A IL191636A (en) 2005-12-07 2008-05-22 Neurolipeptide-2 receptor agonists, medicinal preparations containing them and their use in the preparation of drugs
NO20082445A NO20082445L (no) 2005-12-07 2008-05-28 Neuropeptid-2 reseptor-agonister

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US74807105P 2005-12-07 2005-12-07
US60/748,071 2005-12-07
US85524906P 2006-10-30 2006-10-30
US60/855,249 2006-10-30

Publications (2)

Publication Number Publication Date
WO2007065808A2 WO2007065808A2 (fr) 2007-06-14
WO2007065808A3 true WO2007065808A3 (fr) 2007-08-02

Family

ID=37964711

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/068924 Ceased WO2007065808A2 (fr) 2005-12-07 2006-11-27 Agonistes du récepteur du neuropeptide-2

Country Status (18)

Country Link
US (2) US7642244B2 (fr)
EP (1) EP1962959B1 (fr)
JP (1) JP5000663B2 (fr)
KR (1) KR101059602B1 (fr)
AR (1) AR057222A1 (fr)
AT (1) ATE549350T1 (fr)
AU (1) AU2006324076A1 (fr)
BR (1) BRPI0619573A2 (fr)
CA (1) CA2630649A1 (fr)
EC (1) ECSP088511A (fr)
ES (1) ES2381497T3 (fr)
IL (1) IL191636A (fr)
MA (1) MA30142B1 (fr)
NO (1) NO20082445L (fr)
NZ (1) NZ568772A (fr)
RU (2) RU2430108C2 (fr)
TW (1) TWI321474B (fr)
WO (1) WO2007065808A2 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9765153B2 (en) 2012-07-04 2017-09-19 Hoffmann-La Roche Inc. Anti-biotin antibodies and methods of use
US9925272B2 (en) 2012-07-04 2018-03-27 Hoffmann-La Roche Inc. Anti-theophylline antibodies and methods of use
US10407511B2 (en) 2014-01-03 2019-09-10 Hoffmann-La Roche Inc. Covalently linked helicar-anti-helicar antibody conjugates and uses thereof
US10517945B2 (en) 2012-07-04 2019-12-31 Hoffman-La Roche Inc. Covalently linked antigen-antibody conjugates
US10519249B2 (en) 2014-01-03 2019-12-31 Hoffmann-La Roche Inc. Covalently linked polypeptide toxin-antibody conjugates

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010069242A (ko) * 2000-09-05 2001-07-25 양우용 저주파 물리치료 겸용 혈압 강하기
EP1962959B1 (fr) * 2005-12-07 2012-03-14 F. Hoffmann-La Roche AG Agonistes du récepteur du neuropeptide-2
US8299023B2 (en) * 2008-09-17 2012-10-30 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists
WO2010052144A2 (fr) * 2008-11-05 2010-05-14 F. Hoffmann-La Roche Ag Agonistes du récepteur 2 de neuropeptide (y-2r) et leurs utilisations
WO2011002066A1 (fr) 2009-07-02 2011-01-06 武田薬品工業株式会社 Peptide et son utilisation
CN102573888A (zh) * 2009-09-18 2012-07-11 诺和诺德公司 长效y2 受体激动剂
EP2488195A2 (fr) * 2009-10-13 2012-08-22 F. Hoffmann-La Roche AG Agonistes du récepteur du neuropeptide-2 (y-2r)
MX345501B (es) 2010-12-16 2017-02-02 Novo Nordisk As Composiciones solidas que comprenden agonista de glp-1 y sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico.
BR112013014644A2 (pt) * 2011-01-03 2017-03-07 F Hoffmann - La Roche Ag composição farmacêutica e complexo
HRP20181447T1 (hr) 2012-03-22 2018-11-02 Novo Nordisk A/S Pripravci glp-1 peptida i njihova priprava
RS58039B1 (sr) 2013-05-02 2019-02-28 Novo Nordisk As Oralno doziranje glp-1 jedinjenja
CN105764919B (zh) 2013-11-15 2021-04-27 诺和诺德股份有限公司 在位置35具有β-高精氨酸置换的hPYY(1-36)
BR112016010383A2 (pt) 2013-11-15 2017-12-05 Novo Nordisk As compostos de pyy seletivos e usos dos mesmos
MX373097B (es) 2014-01-03 2020-04-27 Hoffmann La Roche Anticuerpos biespecíficos anti-hapteno/anti-receptor de barrera hematoencefálica, complejos de los mismos y su uso como transportadores a través de la barrera hematoencefálica.
MA41898A (fr) * 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
MY187047A (en) 2015-06-12 2021-08-27 Novo Nordisk As Selective pyy compounds and uses thereof
KR102647171B1 (ko) 2018-02-02 2024-03-15 노보 노르디스크 에이/에스 Glp-1 작용제 및 n-(8-(2-하이드록시벤조일)아미노)카프릴산의 염을 포함하는 고형 조성물
WO2021094259A1 (fr) 2019-11-11 2021-05-20 Boehringer Ingelheim International Gmbh Agonistes du récepteur npy2
KR20230045088A (ko) 2020-08-07 2023-04-04 베링거 인겔하임 인터내셔날 게엠베하 가용성 npy2 수용체 작용제

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004066966A2 (fr) * 2003-01-17 2004-08-12 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Analogues du peptide yy

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
HUT73494A (en) * 1993-03-29 1996-08-28 Univ Cincinnati Analogs of peptide yy and uses thereof
AUPO029096A0 (en) 1996-06-05 1996-07-04 Crc For Biopharmaceutical Research Pty Ltd Npy y2 agonists
US6013633A (en) 1997-08-07 2000-01-11 University Of Cincinnati Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm
BR0012804A (pt) * 1999-07-28 2002-08-06 Ortho Mcneil Pharm Inc Derivados de amina e amida como ligandos para o receptor de neuropeptìdeo y y5 útil no tratamento da obesidade e outros distúrbios
SI1620118T1 (sl) 2003-04-08 2014-11-28 Yeda Research And Development Co., Ltd. Reverzibilna pegilirana zdravila
WO2005053726A1 (fr) 2003-11-25 2005-06-16 Bayer Pharmaceuticals Corporation Agonistes selectifs du recepteur de neuropeptide y2
EP1718671A2 (fr) 2004-02-23 2006-11-08 Rheoscience A/S Analogues du peptide yy
US7410949B2 (en) * 2005-01-18 2008-08-12 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists and uses thereof
WO2006091505A2 (fr) 2005-02-24 2006-08-31 Bayer Pharmaceuticals Corporation Agonistes du recepteur y de neuropeptide
EP1962959B1 (fr) * 2005-12-07 2012-03-14 F. Hoffmann-La Roche AG Agonistes du récepteur du neuropeptide-2
WO2007085887A1 (fr) 2006-01-27 2007-08-02 Pfizer Products Inc. Agonistes du pyy et leurs utilisations

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004066966A2 (fr) * 2003-01-17 2004-08-12 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Analogues du peptide yy

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BECK-SICKINGER A G ET AL: "STRUCTURE-ACTIVITY RELATIONSHIPS OF CARBOXYL-TERMINAL NEUROPEPTIDE Y PEPTIDE SEGMENTS AND ANALOGUES COMPOSED OF SEQUENCE 1-4 LINKED TO 25-36", EUROPEAN JOURNAL OF BIOCHEMISTRY, BERLIN, DE, vol. 194, no. 2, 1990, pages 449 - 456, XP002376459, ISSN: 0014-2956 *
BOGGIANO M M ET AL: "PYY3-36 as an anti-obesity drug target", OBESITY REVIEWS, BLACKWELL SCIENCE, GB, vol. 6, no. 4, November 2005 (2005-11-01), pages 307 - 322, XP002376517, ISSN: 1467-7881 *
KIRBY D A ET AL: "Defining structural requirements for neuropeptide Y receptors using truncated and conformationally restricted analogues", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 36, no. 3, 5 February 1993 (1993-02-05), pages 385 - 393, XP002333099, ISSN: 0022-2623 *
KIRBY D A ET AL: "Y1 and Y2 receptor selective neuropeptide Y analogues: evidence for a Y1 receptor subclass", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 38, no. 22, 27 October 1995 (1995-10-27), pages 4579 - 4586, XP002306036, ISSN: 0022-2623 *
KRSTENANSKY J L ET AL AMERICAN PEPTIDE SOCIETY INC: "NPY AND PYY ANALOGS AS ANTISECRETORY AGENTS", PEPTIDES : CHEMISTRY AND BIOLOGY. CAMBRIDGE, JUNE 16 - 21, 1991, PROCEEDINGS OF THE AMERICAN PEPTIDE SYMPOSIUM, LEIDEN, ESCOM, NL, vol. SYMP. 12, 1991, pages 136 - 137, XP002306038 *
KRSTENANSKY J L ET AL: "Centrally truncated and stabilized porcine neuropeptide Y analogs: design, synthesis, and mouse brain receptor binding", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 86, no. 12, June 1989 (1989-06-01), pages 4377 - 4381, XP002376516, ISSN: 0027-8424 *
SHECHTER ET AL: "Reversible PEGylation of peptide YY3-36 prolongs its inhibition of food intake in mice", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 579, no. 11, 25 April 2005 (2005-04-25), pages 2439 - 2444, XP005390209, ISSN: 0014-5793 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9765153B2 (en) 2012-07-04 2017-09-19 Hoffmann-La Roche Inc. Anti-biotin antibodies and methods of use
US9925272B2 (en) 2012-07-04 2018-03-27 Hoffmann-La Roche Inc. Anti-theophylline antibodies and methods of use
US10517945B2 (en) 2012-07-04 2019-12-31 Hoffman-La Roche Inc. Covalently linked antigen-antibody conjugates
US12023378B2 (en) 2012-07-04 2024-07-02 Hoffmann-La Roche Inc. Covalently linked antigen-antibody conjugates
US10407511B2 (en) 2014-01-03 2019-09-10 Hoffmann-La Roche Inc. Covalently linked helicar-anti-helicar antibody conjugates and uses thereof
US10519249B2 (en) 2014-01-03 2019-12-31 Hoffmann-La Roche Inc. Covalently linked polypeptide toxin-antibody conjugates

Also Published As

Publication number Publication date
EP1962959A2 (fr) 2008-09-03
NZ568772A (en) 2010-05-28
BRPI0619573A2 (pt) 2011-10-04
ES2381497T3 (es) 2012-05-28
IL191636A (en) 2012-10-31
RU2011105310A (ru) 2012-08-20
IL191636A0 (en) 2008-12-29
RU2008127265A (ru) 2010-01-20
CA2630649A1 (fr) 2007-06-14
MA30142B1 (fr) 2009-01-02
EP1962959B1 (fr) 2012-03-14
KR20080082672A (ko) 2008-09-11
JP2009518349A (ja) 2009-05-07
AR057222A1 (es) 2007-11-21
KR101059602B1 (ko) 2011-08-25
TW200806311A (en) 2008-02-01
US7642244B2 (en) 2010-01-05
US20100137223A1 (en) 2010-06-03
ATE549350T1 (de) 2012-03-15
US8268784B2 (en) 2012-09-18
NO20082445L (no) 2008-09-03
ECSP088511A (es) 2008-07-30
AU2006324076A1 (en) 2007-06-14
TWI321474B (en) 2010-03-11
RU2430108C2 (ru) 2011-09-27
JP5000663B2 (ja) 2012-08-15
US20070135351A1 (en) 2007-06-14
WO2007065808A2 (fr) 2007-06-14

Similar Documents

Publication Publication Date Title
WO2007065808A3 (fr) Agonistes du récepteur du neuropeptide-2
WO2010052144A3 (fr) Agonistes du récepteur 2 de neuropeptide (y-2r) et leurs utilisations
WO2007060140A3 (fr) Inhibiteurs de diacylglycérol acyltransférase (dgat)
WO2007107470A3 (fr) Pyrazoles utiles comme inhibiteurs de 11-beta-hsd-1
WO2007082808A3 (fr) Thiazoles en tant qu'inhibiteurs de 11 beta-hsd1
WO2011045232A3 (fr) Agonistes du récepteur du neuropeptide-2 (y-2r)
TW200637874A (en) Peptides with neuropeptide-2 receptor (Y2R) agonist activity
WO2009010416A3 (fr) Inhibiteurs de 11b-hydroxystéroïde déshydrogenase
IL187005A0 (en) Diacylglycerol acyltransferase inhibitors
WO2007003962A3 (fr) Agonistes de gpcr
WO2007003961A3 (fr) Agonistes de gpcr
MX2007010532A (es) Derivados de amida de acido 1-sulfonil-piperidina-3-carboxilico como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa para el tratamiento de diabetes mellitus tipo ii.
MX2009012285A (es) Inhibidores de diacilglicerol aciltransferasa.
TW200745052A (en) Thyroid hormone receptor agonists
WO2007135527A3 (fr) Composés de benzimidazolyle
MX2009006474A (es) Derivados de benzamida como agonistas del receptor ep4.
MX2009007180A (es) Agonistas del receptor acoplado a la proteina g de la piperidina.
NO20074872L (no) Pyrazoler
TN2009000180A1 (en) NOVEL 1,4-BENZOTHIEPIN-l,1-DIOXIDE DERIVATIVES WHICH ARE SUBSTITUTED WITH BENZYL GROUPS, METHOD FOR PRODUCING DRUGS CONTAINING SAID COMPOUNDS AND USE THEREOF
WO2006011050A3 (fr) Derives de pyridine
WO2006104826A3 (fr) Composes antagonistes du recepteur du glucagon, compositions renfermant de tels composes et methodes d'utilisation
WO2005075425A3 (fr) Derives de bisaryluree
TW200613243A (en) Novel compounds
WO2008006795A3 (fr) Composés d'indole
MX2009006010A (es) Derivados de amina y su uso en enfermedades mediadas por el adrenoreceptor beta 2.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680044377.0

Country of ref document: CN

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006830133

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: CR2008-010004

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: 191636

Country of ref document: IL

Ref document number: 2630649

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 12008501297

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 568772

Country of ref document: NZ

Ref document number: 2008060923

Country of ref document: EG

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/007186

Country of ref document: MX

Ref document number: 4830/DELNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2008543768

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006324076

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020087016291

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2008127265

Country of ref document: RU

ENP Entry into the national phase

Ref document number: 2006324076

Country of ref document: AU

Date of ref document: 20061127

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006324076

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2006830133

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0619573

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080609